Home Companies GlaxoSmithKline

GlaxoSmithKline

Latest

GEN 40

StockWatch: After Bluebird’s Second Approval, Investors Are Looking for More

Coronavirus

StockWatch: Novavax Sinks with Revenue Forecast, Vaccine Demand

Vaccine Development

GSK to Acquire Affinivax for Up to $3.3B, Bolstering Vaccine Portfolio

Oncologics

StockWatch: Sierra Oncology Surges on $1.9B GSK Acquisition

HBV

And Then There Were Four: VBI Scores First FDA Approval with Hepatitis B Vaccine

GlaxoSmithKline

U.S. OKs EUA for Genentech’s Actemra vs. COVID-19; Halts Distribution of...

GlaxoSmithKline

GSK, Vir Seek Emergency Use Authorization for COVID-19 Antibody

GlaxoSmithKline

Sanofi, GSK Launch Phase II Trial of “Refined” COVID-19 Vaccine

Horizontal DNA Double Helixx

GlaxoSmithKline

DARPA to Fund CRISPR Diagnostics Using Mammoth, IDbyDNA Technologies

GlaxoSmithKline

NVIDIA Powers Up in Drug Discovery

GlaxoSmithKline

As Pressure Mounts, CEOs Commit to Science, Safety in Developing COVID-19...

GlaxoSmithKline

Sanofi, GSK Advance COVID-19 Vaccine into the Clinic

GlaxoSmithKline

At Orchard, Moving from Pruning to Planting

GlaxoSmithKline

GSK Invests $250M in Vir as Companies Partner on COVID-19 Candidates

GlaxoSmithKline

GSK, Immatics Ink Up-to-$1B Cancer Immunotherapy Collaboration

12 3 Page 1 of 3